Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Despite dynamic drug and vaccine developmental processes to reduce the disease burden of COVID 19, still the options for treatment are very limited.
📊
Key Findings & Data:VIP inhibits SARS COV-2 gene replication in human monocytes and viral replication in Calu -3 cells thus further reducing the generation of proinflammatory mediators Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials Initial binding of Aviptadil with nsp10 & nsp 16 which may inhibit the 2 -O-MTase activity of the SARS-CoV nsp10/16 complex Aviptadil as a synthetic VIP has already been proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries.
💡
Conclusion & Impact:Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Despite dynamic drug and vaccine developmental processes to reduce the disease burden of COVID 19, still the options for treatment are very limited. Vasoactive peptide (VIP) has diversified physiological action with specific features of lung protection-related activities. VIP inhibits SARS COV-2 gene replication in human monocytes and viral replication in Calu -3 cells thus further reducing the generation of proinflammatory mediators Aviptadil, a synthetic form of VIP, is the only pulmonary therapeutic agent to have been granted Fast Track status by the US FDA and to be allowed into both phase 2/3 clinical trials Initial binding of Aviptadil with nsp10 & nsp 16 which may inhibit the 2 -O-MTase activity of the SARS-CoV nsp10/16 complex Aviptadil as a synthetic VIP has already been proved to be an effective option in the treatment of severe respiratory failures due to sepsis and other related lung injuries. Interim analysis results of this drug use in respiratory failures caused by SARS COV-2 has evolved a new hope in regards to safety and efficacy. Final results from recently completed as well as all currently ongoing trials will clarify the class effect of this drug in the treatment of COVID 19 in future days.
🔖
Cite This Article
CHAKRABORTY, D. S., CHOUDHURY, S., LAHİRY, S. (2022). AVIPTADIL; Class effect of a Synthetic VIP as a treatment option in COVID 19 patients with severe respiratory failure. Medicine Science, Cilt: 11 - Sayı: 1, 433–438. https://ajindex.com/articles/579606
Chacko J, Unais M. Pharmacologic treatment of COVID-19: Evidencebased update. Indian J Respir Care. 2021
10,Suppl S1:34-8 2. Heustess AM, Allard MA, Thompson DK, et al. Clinical management of COVID-19: A Review of pharmacological treatment options. Pharmaceuticals. 2021
Said SI, Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature.1970
Li L, Hua S, Yue S, et al. Vasoactive intestinal polypeptide induces surfactant protein A expression in ATII cells through activation of PKC/c- Fos pathway. Peptides. 2010
Mossel EC, Wang J, Jeffers S, et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. 2008
Tang H, Welton A, Ganea D. Neuropeptide regulation of cytokine expression: Effects of VIP and RO 25-1553. J Interferon Cytokine Res. 1995
Voice JK, Grinninger C, Kong Y, et al. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell targeted type II VIP receptor transgenic mice. J Immunol. 2003
Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med. 2007
Delgado, Mario Martínez, Carmen Pozo, David et al. Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-6. J Immunol. 1999
Berisha HI, Bratut M, Bangale Y, et al. New evidence for transmitter role of VIP in the airways: Impaired relaxation by a catalytic antibody. PulmPharmacolTher. 2002
Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activationinduced cell death is downregulated by vasoactive intestinal peptide in Th2 but not Th1 effectors J Immunol. 2005
97–110. 12. Said SI. Vasoactive intestinal peptide in the lung. Ann N Y Acad Sci. 1988
Hasaneen NA, Foda HD, Said SI. Nitric oxide and vasoactive intestinal peptide as co-transmitters of airway smooth-muscle relaxation: analysis in neuronal nitric oxide synthase knockout mice. Chest. 2003
Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians. 1984